drugset / Trial / NCT00587015
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A dose-escalation study to estimate the maximum tolerated dose(MTD) of CAT-8015 that can be safely administered to a patient.
Timeline
- Start
- 2007-08
- Primary completion
- 2008-03
- Completion
- 2009-10
Outcome
Outcome not reported
Stopped: “Due to a lack of IP supply and then terminated because they were combined into one new study with the new IP formulation.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Moxetumomab Pasudotox | Protein / enzyme biologic | 5 ug/kg | — |
| Comparator | Moxetumomab Pasudotox | Protein / enzyme biologic | 10 ug/kg | — |
| Comparator | Moxetumomab Pasudotox | Protein / enzyme biologic | 20 ug/kg | — |
| Comparator | Moxetumomab Pasudotox | Protein / enzyme biologic | 30 ug/kg | — |
| Comparator | Moxetumomab Pasudotox | Protein / enzyme biologic | 40 ug/kg | — |
| Comparator | Moxetumomab Pasudotox | Protein / enzyme biologic | 50 ug/kg | — |
| Comparator | Moxetumomab Pasudotox | Protein / enzyme biologic | 60 ug/kg | — |